Subscribe to our Newsletters !!

    Genomics

    Researcher find a gene mutation connected to schizophrenia

    Researchers at The Feinstein Institutes for Medical Research, in collaboration with Columbia University, have identified a gene mutation that could result in schizophrenia, a chronic brain disease that affects nearly 1 percent of the planet’s inhabitants. The findings, published in today in Neuron, could lead to novel treatment strategies. The research group, headed by Todd

    Researchers describe the systems that manage embryonic stem cells

    Scientists at the Proteomics Core Unit of the Spanish National Cancer Research Centre (CNIO), headed by Javier Muñoz, have clarified the mechanisms, unknown to date, included in maintaining embryonic stem cells in the best possible condition for their use in regenerative medicine. The results, published in Nature Communications, helps to find novel stem-cell therapies for

    NIAID sets up a clinical research organization to improve comprehension of child asthma

    This nationwide network will conduct observational studies and clinical trials to improve understanding of asthma and develop prevention and treatment approaches tailored to children of low-income families residing in urban communities. NIAID plans to provide approximately $70 million over seven years to support the CAUSE network. This new initiative expands and extends NIAID’s long-standing attempts

    Researchers develop experimental direct-acting antiviral treatment to treat COVID-19

    An international team of scientists from the Menzies Health Institute Queensland (MHIQ) at Griffith University and from City of Hope, a research and treatment center for cancer, diabetes and other life-threatening diseases in the U.S., have developed an experimental direct-acting antiviral therapy to treat COVID-19. Conventional antivirals reduce symptoms and help people recover earlier. Examples

    Novel antibody candidate shows powerful binding to different SARS-CoV-2 variant mutations

    Twist Bioscience Corporation today reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent binding to diverse SARS-CoV-2 variant mutations, including strains with the E484K, N501Y, D614G, Y453F and K417N mutations in pseudovirus assays, indicating this therapeutic antibody may be effective in treating many strains of COVID-19. The Coronavirus Immunotherapy Consortium (CoVIC) is an academic-industry-non-profit